I am still fairly new to FTT and have read about the past trial. Have I got it right - that the trial was a success yet the company incorrectly structured it as a device and not a drug so it was useless in a commercial sense?
Also the treated patients were compared to another study of "best practice' so there was some ambiguity there? (no placebo group)
Probably worded my question a little wrong but I hope you get what I mean...
- Forums
- ASX - By Stock
- DLM
- Ann: Last patient completes treatment in VLU Ph 2 Clinical Trial
Ann: Last patient completes treatment in VLU Ph 2 Clinical Trial, page-18
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
RNU
Renascor wins a funding boost given it wants to produce a critical mineral – but $5M award pales in comparison to some
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable